Nuvectis Pharma (NVCT) investor relations material

Program initiation and strategic overview

• Initiated Phase 1b study for NXP-900, a selective oral SRC S1 kinase inhibitor, targeting serious unmet needs in oncology and advanced solid tumors with specific genetic alterations.

• NXP-900 offers a pipeline-in-a-pill opportunity, with potential to address multiple cancers and transform the company’s position in precision oncology.

• Strong cash position of approximately $39 million as of June 30, 2025, providing over two years of operational runway to reach key milestones.

• Recent acquisition of shares by a prominent healthcare institutional investor signals confidence in the program.

• Program follows successful completion of Phase 1a dose escalation and drug-drug interaction studies.

Clinical background and study design

• Phase 1a dose escalation in 33 patients showed good tolerability, with no dose-limiting toxicity reached and mostly mild adverse events.

• Achieved >90% inhibition of SRC autophosphorylation at clinically relevant doses, indicating robust target engagement.

• Unique mechanism of action enables inhibition of both catalytic and scaffolding functions, differentiating NXP-900 from other SRC inhibitors.

• Drug-drug interaction study showed NXP-900 is a weak CYP3A inducer, supporting combination with EGFR and ALK inhibitors.

• Protocol designed to maximize likelihood of observing therapeutic effect based on robust preclinical and early clinical data.

Patient populations and study approach

• Phase 1b will evaluate NXP-900 as monotherapy and in combination, focusing on advanced cancers with YES1 amplification, FAT1 or NF2 mutations, and other Hippo pathway alterations.

• Single agent arm targets YES1 amplified or FAT1 mutated NSCLC, NF2 mutated mesothelioma and renal cancer, and other tumors with relevant Hippo Pathway alterations.

• Combination strategy aims to overcome acquired resistance to EGFR (osimertinib) and ALK (lorlatinib) inhibitors in NSCLC.

• Genetic alterations can be identified using widely available next-generation sequencing panels.

• Combination arm will evaluate NXP900 with EGFR and ALK inhibitors in NSCLC patients who developed resistance to these treatments.